Pay in 4 interest-free payments of $13.75 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
KYA1797K can effectively suppress the growth of CRCs harboring APC and KRAS mutations
selective and cell permeable inhibitor of the bromodomain and extra terminal (BET) family proteins BRD2 and BRD4 with IC50 of ~98 nM and 220 nM respectively
41(7):393-403
N106 treatment increases contractile properties of cultured rat cardiomyocytes and significantly improves ventricular function in mice with heart failure
CAS Number: 1418033-25-6
CC-930 - CAS# 899805-25-5 Catalog No.:M6544-10 KYA1797K can effectively suppress theCC 930, also known as Tanzisertib, CAS No. 899805 25 5, is a potent, selective, and orally active JNK inhibitor with potential antifibrotic activity. CC 930 entered Phase I clinical trials. Tanzisertib may have potential use for prevention and treatment of dermal fibrosis. Selective inhibition of JNK by CC 930 exerted potent antifibrotic effects in vitro and in different models in vivo. JNK might thus be a novel molecular target for the treatment of
US$ 25.00
US$ 69.95
US$ 2699.50
US$ 20.00
US$ 12.00
US$ 18.00
US$ 30.00
US$ 12.00
US$ 16.00
US$ 12.00
US$ 15.00